key: cord-0902980-nob24220
authors: Kuipers, M.T.; van Zwieten, R.; Heijmans, J.; Rutten, C.E.; de Heer, K.; Kater, A.P.; Nur, E.
title: G6PD deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine
date: 2020-05-10
journal: Am J Hematol
DOI: 10.1002/ajh.25862
sha: 63350712b8b0f24fd0a28534fc44bcf082b243be
doc_id: 902980
cord_uid: nob24220

nan

To the Editor:

Novel coronavirus disease (COVID-19) is spreading around the world and although clinical data are limited, immunomodulatory agents such as chloroquine and hydroxychloroquine are used as off-label treatment. 1 While these medications have an established clinical safety profile for their common use, e.g. malaria, their efficacy and safety in COVID-19 pneumonia remains unclear 1 as most of the evidence to support use of chloroquine or the less toxic hydroxychloroquine against the disease comes from a small single arm trial. 2 As we demonstrate in this correspondence, the use of chloroquine for treatment of patients with COVID-19 infection is not without risks.

A 56-year-old man, with a medical history of diabetes mellitus type 2, presented to the emergency department with a 6 day history of myalgia and a dry cough. Oxygen saturation was 94% with room air and respiratory rate 24/min. There was no fever and his pulse and blood pressure were normal. COVID-19 was suspected which was confirmed by a real-time-PCR assay. A chest CT scan showed bilateral ground glass opacities. The patient was admitted for observation on a COVID-19 ward. During the following 2 days, his condition deteriorated with increasing need for oxygen administration. On the third day of admission his peripheral oxygen saturation dropped to 83% despite the use of a non-rebreathing mask with 15

This article is protected by copyright. All rights reserved.

liters/min of oxygen. His respiratory rate was 30/minute. He was admitted to the intensive care unit (ICU) for initiation of mechanical ventilation. Treatment with chloroquine was started consisting of a starting dose of 600 mg followed by 300 mg twice a day (for 5 days). 1 Initial ICU laboratory results demonstrated a hemoglobin level of 11.4 g/dL (reference 13.7-17.7 g/dL), 12 hours later his hemoglobin level dropped to 8.9 g/dL and additional laboratory investigations demonstrated signs of severe hemolysis. A peripheral blood smear revealed findings consistent with hemolysis ( Figure 1) . Arterial blood gas results demonstrated increased levels of methemoglobin (9.1%; reference <1.5%). Given his ethnic background (African-Caribbean), glucose-6-phospate dehydrogenase (G6PD) deficiency was suspected and chloroquine was stopped. 3 He received 3 units of packed red blood cells in the following 48 hours. Although his methemoglobin level was relatively low, 1000 milligram ascorbic acid (vitamin C) was administered iv 4 times a day for 2 days, to help optimize his oxygenation. His methemoglobin normalized within 6 days and laboratory testing for G6PD deficiency confirmed very low G6PD activity in the patient's red blood cells (Figure 1 a, This article is protected by copyright. All rights reserved. due to methemoglobinemia. Hemoglobin is transformed to methemoglobin once ferrous iron (Fe2+) of the heme group is oxidized to ferric iron (Fe3+). Methemoglobin has such a high oxygen affinity that it virtually cannot release its oxygen in the tissues and this usually becomes clinically apparent at a level of 15% or more. 4 However, patients with severe anemia may have symptoms at lower levels. The most frequent cause of methemoglobinemia is exposure to oxidative drugs such as chloroquine. 5,6 Under normal circumstances methemoglobin is rapidly converted back to hemoglobin by the NADH-dependent cytochroom B5-methemoglobin reductase (CYB5R) enzyme. Oxidizing agents may overwhelm this reducing system and cause methemoglobin levels to rise. Mutations affecting the activity of CYB5R enzyme can lead to congenital methemoglobinemia. 5 Molecular analysis of the CYB5R enzyme in our patient, however, did not show any pathogenic variants. Based on this result together with the normalization of the methemoglobin level after chloroquine discontinuation and no medical history of methemoglobinemia, the reducing capacity of the deficient G6PD in our patient was probably overwhelmed by the antioxidant consumption during COVID-19 in combination with chloroquine use.

Widespread off-label use of chloroquine harbors potential benefit but also a risk of harm.

Monitoring of well-known side effects such as QT prolongation, bone marrow suppression, mental disturbances is recommended. 1, This case-report illustrates that hemolytic anemia due to G6PD deficiency is another complication that can occur and exacerbate an already compromised oxygenation in the setting of COVID-19 pneumonia.

Pending results from well-designed clinical trials, we recommend caution with using chloroquine as treatment of COVID-19. If feasible, G6PD deficiency should be ruled out before administering chloroquine in patients with COVID-19.

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19